The use of viral vectors to transfect postmitotic neurons has provided an important research tool, and it offers promise for treatment of neurologic disease. The utility of vectors is enhanced by the use of selective promoters that permit control of the cellular site of expression. One potential clinical application is in the neurorestorative treatment of Parkinson's disease by the induction of new axon growth. However, many of the genes with an ability to restore axons have oncogenic potential. Therefore, clinical safety would be enhanced by restriction of expression to neurons affected by the disease, particularly dopamine neurons. To achieve this goal we have evaluated in vivo three partial sequences of the promoter for human tyrosine hydroxylase, the rate limiting enzyme in catecholamine synthesis. All sequences induced expression in dopamine neurons. None of them induced expression in glia or in nondopaminergic neurons in striatum or cortex. We conclude that these sequences have potential use for targeting dopamine neurons in research and clinical applications.
INTRODUCTION
The use of cell selective promoters to regulate the expression of foreign genes delivered by viral vectors offers many advantages for both research and clinical applications. In the research setting, for example, cell specific promoters have found numerous uses to enhance the specificity of optogenetic approaches. 1 In the clinical realm promoters with specificity have the potential to restrict the cellular site of expression and thereby limit off-target effects. For example, we have recently shown that adult dopamine neurons of the mesencephalon, which are predominantly affected in human Parkinson's disease (PD), can be induced to grow new axons following transduction with constitutively active forms of the kinase Akt or the GTPase hRheb. 2, 3 These observations provide an experimental basis for a new approach to neurorestoration for PD. However, both of these molecules are known to participate in oncogenesis. Therefore, to administer them intracerebrally under the control of a general mammalian promoter for clinical treatment would carry significant risk. For clinical therapeutics the safety of this approach would be greatly enhanced by restricting the expression of these molecules to the desired cellular targets. In the case of PD, for the treatment of its motor manifestations, the relevant population is the dopamine neurons of the substantia nigra pars compacta (SNpc).
The promoter for tyrosine hydroxylase (TH), the rate limiting enzyme in catecholamine biosynthesis, has received extensive prior characterization for achieving selective expression in these neurons. In addition, it provides a number of options for promoter sequences that can be accommodated by the space limitations of an adeno-associated viral (AAV) vector (≤ 4.7 kb). For the purposes of characterizing the human TH promoter (hTHp) sequences that could ultimately be used in gene therapies for human PD, and for transduction of human induced pluripotent stem cells (iPSCs) derived to acquire the dopamine neuron phenotype, we selected three published hTHp sequences that could be accommodated by AAV vector packaging. A 522 bp sequence derived from the 5′ region of the human TH gene was identified by Coker et al. and shown to be sufficient to drive reporter expression with selectivity for a neuronal cell line. 4 This sequence was subsequently used to mediate expression in a human neuroblastoma cell line. 5 Gardaneh and colleagues demonstrated that a striking synergy can be achieved by use of both 5′ and 3′ flanking sequences of the hTHp. 6 A 3.3 kb sequence derived from the 5′ region of the hTHp was found by Kim and colleagues to drive reporter expression in human neuroblastoma cells but not in immature human neural stem cells. 7 The performance of a promoter can be expected to be modified by the cellular context in which it acts. Therefore, since our ultimate goal is to identify promoter sequences that will retain strength and specificity in the in vivo context, we evaluated each of these sequences in living mice by AAV-mediated transduction of the SN and control brain regions.
RESULTS
An initial assessment of each of the three hTHp constructs at 4-6 weeks following injection of the SN revealed no toxicity to dopaminergic neurons. Sections immunostained for TH with thionin counterstain revealed no evidence of dopamine neuron loss or an inflammatory response (data not shown).
A qualitative assessment of TagRFP-T expression mediated by each of the hTHp promoter sequences demonstrated that each was capable of mediating expression in dopamine neurons of the SN (Figure 1 ). However this analysis also revealed that each of the promoter sequences mediated expression in non-TH-positive profiles, and, conversely, failed to express in some TH-positive neurons, thus demonstrating limitations on the specificity and sensitivity for each sequence. The presence of reporter expression in some dopamine neurons but not others led us to question whether selective expression may be related to the presence of dopamine neuron subtypes within the SN. 8, 9 One subtype lies predominantly in the dorsal tier of the SNpc and expresses calbindin; the other resides in the ventral tier and preferentially expresses class 1 aldehyde dehydrogenase (AHD2). 10 Immunofluorescence for these two markers was performed in order to analyze any possible preferential expression by any of the promoter sequences in either of these two subpopulations ( Figure 2 ). Following injection of the SN with each of the three promoter constructs we observed expression of TagRFP-T in both calbindin and AHD2-positive neurons with qualitatively similar abundance (Figure 2 ). Thus, we conclude that patterns of staining for each of the sequences are not due to selective expression in dopaminergic neuron subtypes.
In view of the expression of the reporter in non-TH positive neurons in the SN, we next sought to determine the specificity of the promoter sequences in regions where dopamine neurons are not ordinarily found. For this experiment we injected either the striatum or the cortex with each of the three vectors. At 6 weeks after these injections no reporter expression was observed for any of the sequences in either of these regions, confirming specificity of expression ( Figure 3 ). In the evaluation of nondopaminergic staining in the SN it is especially important to determine whether at the cellular level any expression is observed in nonneural cells such as glia, as they could be a particularly important site of off-target effects. We therefore examined reporter expression in astrocytes that had been identified by immunofluorescent staining for glial fibrillary acidic protein (GFAP). For each of the three partial human promoter sequences we were unable to identify any reporter expression in glia ( Figure 4 ).
In view of the similarity in the performance of these hTHp sequences in these qualitative assessments, we undertook to quantitatively evaluate their strength, specificity, and sensitivity of expression in the SN. We first addressed the abundance of reporter expression in the whole SN following injection of each of the three constructs. The hTHp-5,3-TagRFP-T construct showed the highest number of TagRFP-T-positive neurons (517 ± 81.8), and a statistically significant difference in comparison to hTHp-522-TagRFP-T which had the lowest number of TagRFP-T-positive neurons (251.5 ± 30.7; P = 0.004, one-way analysis of variance) ( Figure 5b ). While there was a trend for hTHp-5,3-TagRFP-t to be higher than hTHp-3.3-TagRFP-T, this difference did not achieve significance.
In order to evaluate the sensitivity and specificity of expression in dopamine neurons of the SN, we quantified the total number of TH-positive neurons, TagRFP-T/Nissl-positive neurons and TagRFP-T/Nissl/TH neurons. The three promoter sequences showed only modest levels of sensitivity for detection of dopamine neurons in the SN ( Table 1 ). The most effective construct was hTHp-522-TagRFP-T which achieved expression in 76% of dopamine neurons within the whole SN and a high of 93% within the SN pars reticulata (SNpr). Surprisingly, the two larger promoter sequences had much lower levels of sensitivity at 33 and 43% respectively for hTHp-5,3-TagRFP-T and hTHp-3.3-TagRFP-T. Given the lack of expression by any of these sequences in nondopaminergic regions such as cortex and striatum it was surprising to find such low levels of specificity in the SN ranging from 20% for hTHp-522-TagRFP-T to 17% for hTHp-5,3-TagRFP-T.
DISCUSSION

Prior studies of these hTHp sequences have been exclusively in vitro.
We demonstrate here that each of these sequences has the ability to mediate reporter expression in dopamine neurons of the SN in vivo. Therefore, they have potential use in clinical applications.
Our primary goal in assessing these sequences was to determine their specificity, in order to ascertain their potential for minimizing expression in nondopaminergic cells, and thereby reducing the likelihood of off-target effects. Achievement of this goal would be an important step forward in the development of Akt and hRheb for use in gene therapy applications in neurorestorative treatment of PD. Given the oncogenic potential of these molecules, we particularly sought to determine the use of these sequences to minimize expression in glial, as they are the predominant cellular source of primary human brain tumors. We have found that none of these sequences induced reporter expression in astrocytes in the SN. Admittedly some of the neuronal specificity achieved may have been due to the known neurotropic properties of AAV vectors. Nevertheless in our own experience with AAV 2/1 injections of the SN, we have occasionally observed glia to be transduced, particularly near the injection site. In addition, for reasons that are not clear, occasional expression is observed in glia for some particular transgenic proteins when the chicken beta actin promoter is used to mediate expression. Therefore, we believe that these hTHp sequences provide an additional margin of safety for avoiding transduction of glial cells. Furthermore, it may be possible in the future to achieve additional specificity of transduction by use of select or modified AAV serotypes. 11 We also sought to determine if these sequences limited expression among neurons to the dopamine neurons of the SN. Both Akt and hRheb have biologic effects on nondopaminergic neurons, 12, 13 so expression of either molecule in adjacent nondopaminergic neurons could have off target effects such as disturbances in motor control due to altered function in these complex basal ganglia circuits. Injections of stratum and cortex with each of the hTHp sequences failed to induce any reporter expression, so in this assessment excellent specificity was achieved. However, surprisingly, within the SN itself, where patterns of expression were assessed by the identification of dopaminergic neurons by immunohistochemistry, specificity appeared to be much less, with 80% or more of the TagRFP-T-positive neurons not expressing TH. There are several possible reasons for this discrepancy. It is well known that immunohistochemistry does not detect all target antigens in tissue sections, due to limitations on the tissue penetration of protein reagents, and in particular to the entry of antibodies into the cell. Thus immunostaining will produce false negatives for the dopaminergic phenotype.
In addition, we have observed that transduction of dopamine neurons with transgenes under either the chicken beta actin or the TH promoter can result in a suppression of expression of endogenous proteins, such as TH, used to identify the cell phenotype (personal observations). These considerations would not however explain the appearance of reporter expression in the SNpr where few dopamine neurons are located. These neurons are predominantly of the gamma-aminobutyric acid-ergic (GABAergic) phenotype. While TH is expressed in some GABAergic neurons of the brain, particularly those in the olfactory bulb, 14 it is not known to be expressed in GABAergic neurons of the SNpr. Therefore, the reason why reporter is expressed in nondopaminergic neurons of the SNpr and yet not that of the striatum or cortex is unknown.
Among these hTHp sequences we did not identify an important difference in specificity. There was a trend for hTHp-522-TagRFP-T to be more specific but this difference was small. hTHp-522-TagRFP-T did however demonstrate a greater sensitivity for the detection of dopaminergic neurons; it successfully expressed reporter in 76% of the TH-positive neurons, whereas hTHp-5,3-TagRFP-T and hTHp-3.3-TagRFP-T achieved expression in only 33 and 40% of instances respectively.
We conclude that all of these hTHp sequences are capable of mediating expression in dopamine neurons in vivo with similar specificity in the SN. Because hTHp-522 as the smallest allows more space in the cassette for transgenes, and offers a higher level of sensitivity for achieving expression in SN dopamine neurons it may be the most useful in practical applications.
MATERIALS AND METHODS
Production of AAV viral vectors
All vectors used for these studies were AAV1 serotype. A plasmid carrying a photostable fluorescent reporter TagRFP-T 15 was obtained from Axxora (San Diego, CA). TagRFP-T DNA was amplified and cloned into an AAV backbone with the chicken β-actin promoter, and a woodchuck postregulatory element (WPRE) at the 3′ end (pBL). Three partial sequences of the hTHp were based on GenBank Acc# AY211521: 522bp (spanning from −491 to +31), 4 a combination of 5′-flanking region (spanning from −509 to +1) and a 976 bp segment of 3′-flanking region DNA extending in the 3′ direction from the PolyA signal, 6 and 3.3 kb (spanning from −3204 to +3) 7 were produced by polymerase chain reaction amplification from human genomic DNA (Promega, Madison, WI) and subcloned in pGEM-T vector system (Promega).
The following primers pairs were used: for the 522bp sequence, 5′-AGACACACGGCCTGGAATCT-3′ (forward), 5′-CCTGTGGCGTGGTGGCGTCGG GGGTGGGCATGGCTCAGTGTGGA-3′ (reverse); and for the 3.3 kb sequence, 5′-GACCAGTGTCTTGGGAGTTG-3′ (forward), 5′-CATGGCTCAGTGTGGAGGTCC GG-3′ (reverse). For the 5,3 combined promoter the 5′ flanking sequence was created from the 3.3 kb fragment by subcloning of its 3′terminus. Primers for the 3′ flanking region were based on GenBank Acc#NG_ 008128: 5′-TCACAATAAAAGAAACTGTGGTCT-3′ (forward), 5′-ACACCCCCA GCTGCAACCT-3′ (reverse). The chicken β-actin promoter in pBL-Tag-RFP-T was then replaced by each of these three partial sequences of hTHp to generate three different constructs: hTHp-522-TagRFP-T, hTHp-5,3-TagRFP-T, and hTHp-3.3-TagRFP-T. All nucleotide sequences in the AAV packaging constructs were confirmed before AAV production. AAVs were produced by the University of North Carolina Viral Vector Core (Chapel Hill, NC). The titer of AAV hTHp-522-TagRFP-T was 5 × 10 12 viral genomes (vg)/ml; for AAV hTHp-5,3-TagRFP-T it was 1 × 10 12 vg/ml, and for AAV hTHp-3.3-TagRFP-T it was 2 × 10 12 vg/ml.
Intracerebral AAV injections
Adult (8 weeks , and 4 × 10 9 vg. All injection procedures, as described above, were approved by the Columbia University Institutional Animal Care and Use Committee.
Tissue processing Post 6 weeks of AAV injections, mice were deeply anaesthetized and perfused intracardially with 0.9% NaCl followed by 4% paraformaldehyde in 0.1 mol/l phosphate buffer, pH 7.1. The brain was carefully removed and processed for sectioning on either a Vibratome (50 µm horizontal sections) or cryostat (30 µm coronal sections). For Vibratome sectioning the whole brain was postfixed 48 hours in 4% paraformaldehyde in 0.1 mol/l phosphate buffer, pH 7.1. For cryostat sectioning the brain was blocked into forebrain and midbrain regions. The forebrain was postfixed 48 hours; the midbrain was postfixed according to the specific antibody protocol (see below) and then cryoprotected overnight. Cryostat sections were cut after the brain was rapidly frozen by immersion in isopentane on dry ice. All sections were processed free-floating.
Immuohistochemical staining procedures
Coronal cryostat sections containing SN or striatum (30 µm) and horizontal vibratome sections containing SN (50 µm) were immunostained either for TH (TH, 1:750, polyclonal, Calbiochem, Millipore, Billerica, MA) or calbindin (calbindin, 1:2,500, polyclonal, Swant, Marly, Swizerland) or AHD2 (AHD2, 1:300, polyclonal, Abcam, Cambridge, MA) or GFAP (GFAP, 1:800, monoclonal, Sigma, Ronkonkoma, NY). The midbrain was postfixed 48 hours for AHD2 and calbindin immunostaining, and 72 hours for GFAP staining. For staining with polyclonal antibodies sections were then treated with goat antirabbit AlexaFluor488. For GFAP staining with a monoclonal, sections were first treated with biotinylated antimouse IgG, followed by streptavidin AlexaFluor488. 
Statistical analysis
Differences between the three constructs were analyzed by one-way analysis of variance and Tukey's post hoc analysis. All statistical analyses were performed using SigmaStat software (version 12) (Systat Software, San Leandro, CA). . The hTHp-522-TagRFP-T group contains more animals because the initial experiment showed more variability than the other groups, so it was repeated twice. All data is included in the analysis. There is a statistical difference between the number of TagRFP-T-positive neurons expressed by hTHp-5,3 and by hTHp-522 (P = 0.004, one-way analysis of variance (ANOVA)). This result was achieved by hTHp-5,3 in spite of being injected at a lower viral genome dose. Bar: 100 µm. AAV, adeno-associated viral; SN, substantia nigra; TH, tyrosine hydroxylase.
To determine the sensitivity and specificity of each promoter sequence for expression in TH-positive dopamine neurons, the relationship between TagRFP-T expression and TH immunostaining was determined for each. In order to facilitate the detection of TagRFP-T expression in neurons, given its punctate nature, the sections were counterstained with a fluorescent Nissl stain, and TagRFP-T expression was counted only if detected in a Nisslpositive neuronal profile. Immunostaining for TH was then visualized and the number of TH-positive neurons positive or negative for TagRFP-T was determined for each of the regions specified. Among the three constructs, the 522 bp sequence of the human TH promoter provides the highest sensitivity and specificity for all considered regions. Two mice were studied for each sequence, and among the six mice 11,107 neurons were assessed.
